Patent · US Active

CD73 inhibitors and pharmaceutical uses thereof

US11530234B2 · kind B2 · utility

0Cited by

9References

21Claims

0Family size

Assignee

RISEN (SUZHOU) PHARMA TECH CO., LTD. · CN

Inventors

Jiasheng LU · Shanghai, CN
Jiamin GU · Suzhou, CN
Gang Chen · Sammamish, US
Feng Zhou · Shanghai, CN
Qiguo ZHANG · Shanghai, CN
Xuli Wang · Suzhou, CN
Xiang JI · Suzhou, CN
Lin Wang · University City, US
Xianqi Kong · Dollard-Des-Ormeaux, CA

Key dates

Filing date	Dec 23, 2020
Grant date	Dec 20, 2022
Priority date	—
Expiry date	Feb 11, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/545
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.